Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03489369
Title Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Symphogen A/S
Indications

lymphoma

Advanced Solid Tumor

Therapies

Sym022

Age Groups:
Covered Countries USA | CAN


No variant requirements are available.